Liver disease.

PubWeight™: 0.76‹?›

🔗 View Article (PMC 2397865)

Published in Postgrad Med J on March 01, 1994


S D Ryder1, R Williams

Author Affiliations

1: Institute of Liver Studies, King's College Hospital, London, UK.

Articles cited by this

(truncated to the top 100)

Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet (1989) 62.23

A genetic model for colorectal tumorigenesis. Cell (1990) 44.37

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89

p53 mutations in human cancers. Science (1991) 31.96

Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41

Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 12.29

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med (1989) 8.10

A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med (1992) 8.06

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67

FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo) (1987) 7.07

Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J (1979) 6.45

Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature (1991) 6.04

Hepatitis A: detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science (1973) 5.82

The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature (1992) 5.71

Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16

The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med (1992) 4.88

Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc Natl Acad Sci U S A (1986) 4.73

Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med (1986) 4.51

The management of fulminant hepatic failure. Prog Liver Dis (1970) 4.37

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32

Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27

Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull (1990) 4.16

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med (1992) 4.05

Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet (1991) 3.97

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A (1991) 3.82

Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet (1989) 3.42

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet (1992) 3.33

Occupational risk for hepatitis C virus infection among New York City dentists. Lancet (1992) 3.31

Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09

Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04

Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet (1989) 2.94

Type A viral hepatitis. New developments in an old disease. N Engl J Med (1985) 2.86

Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med (1992) 2.78

Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg (1992) 2.76

Compact organization of the hepatitis B virus genome. Hepatology (1989) 2.70

Genetic mechanisms of tumor suppression by the human p53 gene. Science (1990) 2.68

Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet (1992) 2.51

A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49

Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet (1992) 2.44

Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology (1992) 2.37

Liver transplantation for type IV glycogen storage disease. N Engl J Med (1991) 2.31

Endoscopic sclerotherapy as compared with endoscopic ligation for bleeding esophageal varices. N Engl J Med (1992) 2.31

Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay. Proc Natl Acad Sci U S A (1992) 2.30

Not all travellers need immunoglobulin for hepatitis A. Br Med J (Clin Res Ed) (1987) 2.28

Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology (1991) 2.25

Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet (1992) 2.25

Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers. Lancet (1989) 2.22

Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut (1976) 2.15

Enzyme-linked immunosorbent assay for diagnosis of acute sporadic hepatitis E in Egyptian children. Lancet (1992) 2.14

Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology (1992) 2.09

Liver resections in cirrhotic patients: a Western experience. World J Surg (1986) 2.05

Role of nitric oxide in gastrointestinal and hepatic function and disease. Gastroenterology (1992) 2.04

Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med (1992) 2.03

Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer (1992) 2.01

Characterization of mixed allogeneic chimeras. Immunocompetence, in vitro reactivity, and genetic specificity of tolerance. J Exp Med (1985) 2.00

Absence of hepatitis C viral RNA from saliva and semen of patients with chronic hepatitis C. Gastroenterology (1992) 1.99

The pathology of hepatitis C. Hepatology (1992) 1.92

An epidemic of hepatitis A attributable to the ingestion of raw clams in Shanghai, China. J Infect Dis (1991) 1.90

Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients. Gastroenterology (1993) 1.90

Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet (1987) 1.87

Type D (delta) hepatitis. JAMA (1989) 1.86

Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol (1987) 1.85

Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer (1988) 1.83

Randomised trial of variceal banding ligation versus injection sclerotherapy for bleeding oesophageal varices. Lancet (1993) 1.82

p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet (1991) 1.81

Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation. Ann Intern Med (1992) 1.80

Hyperdynamic circulation in cirrhosis: a role for nitric oxide? Lancet (1991) 1.78

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology (1988) 1.74

A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci U S A (1986) 1.74

Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology (1987) 1.73

Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology (1992) 1.72

Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J Clin Invest (1989) 1.72

Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med (1992) 1.72

Cancer. A death in the life of p53. Nature (1993) 1.70

Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology (1991) 1.65

Selection for and outcome of liver transplantation in alcoholic liver disease. Gastroenterology (1992) 1.62

Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61

Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet (1988) 1.60

Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology (1992) 1.57

Binding of the major and large HBsAg to human hepatocytes and liver plasma membranes: putative external and internal receptors for infection and secretion of hepatitis B virus. Hepatology (1990) 1.56

A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology (1989) 1.53

The natural history of hepatocellular carcinoma. A study of 100 untreated cases. Cancer (1984) 1.53

Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology (1990) 1.52

Mutations of p53 gene in hepatocellular carcinoma: roles of hepatitis B virus and aflatoxin contamination in the diet. J Natl Cancer Inst (1992) 1.51

Patterns of hepatitis delta virus reinfection and disease in liver transplantation. Gastroenterology (1991) 1.51

Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology (1992) 1.51

Effects of endoscopic injection sclerotherapy on portal hypertensive gastropathy: a prospective study. Gastrointest Endosc (1992) 1.49

Detection of hepatitis B virus DNA in mononuclear blood cells. Br Med J (Clin Res Ed) (1984) 1.49

Technical advances in transjugular intrahepatic portosystemic shunts. Radiographics (1992) 1.48

Prediction of variceal hemorrhage in cirrhosis: a prospective follow-up study. Gastroenterology (1991) 1.47

Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents. Radiology (1985) 1.46

Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol (1992) 1.46

Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology (1992) 1.46

Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation (1992) 1.45

Efficacy of prophylactic sclerotherapy for prevention of a first variceal hemorrhage. Gastroenterology (1992) 1.45

Articles by these authors

(truncated to the top 100)

Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26

Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43

Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64

Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63

Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27

Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07

Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05

Acute liver failure: redefining the syndromes. Lancet (1993) 4.99

Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96

Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57

Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49

Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38

Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27

Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10

Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07

Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78

Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61

Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40

Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36

Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28

Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24

NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21

Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17

Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13

Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09

Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09

Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08

Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06

Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04

Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98

Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98

Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut (1995) 2.96

Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94

More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91

Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88

Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86

The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85

Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85

Liver transplantation after paracetamol overdose. BMJ (1991) 2.81

New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78

Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76

Liver in Felty's syndrome. Br Med J (1970) 2.75

Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70

Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67

Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67

Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65

Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62

Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60

Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60

Liver transplantation. Curr Probl Surg (1979) 2.57

Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53

Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51

Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50

A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50

The systemic inflammatory response syndrome in acute liver failure. Hepatology (2000) 2.47

Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45

Attentional bias in anxiety and depression: the role of awareness. Br J Clin Psychol (1995) 2.43

Developing and deploying a patient safety program in a large health care delivery system: you can't fix what you don't know about. Jt Comm J Qual Improv (2001) 2.42

Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 2.41

Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41

1 -Antitrypsin deficiency and neonatal hepatitis. Br Med J (1972) 2.40

General practice orthopaedic outpatient referrals in North Staffordshire. Br Med J (Clin Res Ed) (1983) 2.38

Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet (1974) 2.37

Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations. Adv Exp Med Biol (1997) 2.35

Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32

Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol (1992) 2.31

Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31

Increased long-term survival in variceal haemorrhage using injection sclerotherapy. Results of a controlled trial. Lancet (1982) 2.30

Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs. Lancet (1970) 2.25

Cytomegalovirus hepatitis in the adult. Lancet (1967) 2.20

Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ (1990) 2.18

Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain. Lancet (1973) 2.17

Assessment of non-mydriatic fundus photography in detection of diabetic retinopathy. Br Med J (Clin Res Ed) (1986) 2.16

Fasting proinsulin concentrations predict the development of type 2 diabetes. Diabetes Care (1999) 2.16

Portal hypertension in idiopathic tropical splenomegaly. Lancet (1966) 2.16

Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet (1968) 2.14

Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J Biol Chem (1989) 2.14

Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax (2002) 2.12

A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology (1995) 2.11

H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trials. Lancet (1977) 2.10

Reduction of absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure. Br Med J (1973) 2.09

Arthropathy of haemochromatosis. Clinical and radiological analysis of 63 patients with iron overload. Ann Rheum Dis (1970) 2.09

Detection, treatment, and follow up of women with Chlamydia trachomatis infection seeking abortion in inner city general practices. BMJ (1989) 2.08

Simple hypothermic preservation for transporting human livers long distances for transplantation. Report of 12 cases. Transplantation (1977) 2.08

Early and intensive therapy of intravascular coagulation in acute liver failure. Lancet (1971) 2.08

Cell-mediated immune responses in chronic liver diseases. Br Med J (1972) 2.05

Inheritance and expression of chimeric genes in the progeny of transgenic maize plants. Biotechnology (N Y) (1990) 2.05

Chondrocalcinosis and arthropathy: studies in haemochromatosis and in idiopathic chondrocalcinosis. Q J Med (1970) 2.03

Development and importance of health needs assessment. BMJ (1998) 2.03

Hereditary spherocytosis with secondary haemochromatosis. Lancet (1968) 2.00

Liver transplantation in man: the frequency of rejection, biliary tract complications, and recurrence of malignancy based on an analysis of 26 cases. Gastroenterology (1973) 1.99

Evidence that hepatitis D virus needs hepatitis B virus to cause hepatocellular damage. Am J Clin Pathol (1992) 1.98

Long term results of venesection therapy in idiopathic haemochromatosis. Q J Med (1976) 1.98

Charcoal haemoperfusion in the treatment of fulminant hepatic failure. Lancet (1974) 1.97

Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet (1982) 1.97

Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction? Br Med J (1972) 1.95

Causal attributions and psychiatric symptoms in survivors of the Herald of Free Enterprise disaster. Br J Psychiatry (1991) 1.95

Bile composition and bile cast formation after transplantation of the liver in man. Transplantation (1975) 1.92

Levodopa in hepatic coma. Lancet (1970) 1.92